{"xml_path": "/Users/leo/Desktop/520 Project 2/ctg-public-xml/NCT0000xxxx/NCT00000102.xml", "nct_id": "NCT00000102", "org_study_id": "NCRR-M01RR01070-0506", "brief_title": "Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets", "official_title": "", "overall_status": "Completed", "why_stopped": "", "phase": "Phase 1/Phase 2", "study_type": "Interventional", "lead_sponsor": "National Center for Research Resources (NCRR)", "collaborators": [], "primary_completion_date": "", "primary_completion_date_type": "", "completion_date": "", "completion_date_type": "", "start_date": "", "start_date_type": "", "study_first_posted": "November 4, 1999", "last_update_posted": "June 24, 2005", "enrollment": "", "enrollment_type": "", "gender": "All", "minimum_age": "14 Years", "maximum_age": "35 Years", "healthy_volunteers": "No", "conditions": ["Congenital Adrenal Hyperplasia"], "condition_mesh_terms": ["Adrenal Hyperplasia, Congenital"], "keywords": [], "interventions": [{"type": "Drug", "name": "Nifedipine", "description": ""}], "intervention_mesh_terms": ["Nifedipine"], "primary_outcomes": [], "secondary_outcomes": [], "number_of_arms": "", "number_of_groups": "", "locations": {"facility_count": 1, "countries": ["United States"]}}
{"xml_path": "/Users/leo/Desktop/520 Project 2/ctg-public-xml/NCT0000xxxx/NCT00000104.xml", "nct_id": "NCT00000104", "org_study_id": "NCRR-M01RR00400-0587", "brief_title": "Does Lead Burden Alter Neuropsychological Development?", "official_title": "", "overall_status": "Completed", "why_stopped": "", "phase": "", "study_type": "Observational", "lead_sponsor": "National Center for Research Resources (NCRR)", "collaborators": ["HRSA/Maternal and Child Health Bureau"], "primary_completion_date": "", "primary_completion_date_type": "", "completion_date": "", "completion_date_type": "", "start_date": "", "start_date_type": "", "study_first_posted": "November 4, 1999", "last_update_posted": "June 24, 2005", "enrollment": "", "enrollment_type": "", "gender": "Female", "minimum_age": "0 Years", "maximum_age": "N/A", "healthy_volunteers": "Accepts Healthy Volunteers", "conditions": ["Lead Poisoning"], "condition_mesh_terms": ["Lead Poisoning"], "keywords": ["lead overburden"], "interventions": [{"type": "Procedure", "name": "ERP measures of attention and memory", "description": ""}], "intervention_mesh_terms": [], "primary_outcomes": [], "secondary_outcomes": [], "number_of_arms": "", "number_of_groups": "", "locations": {"facility_count": 1, "countries": ["United States"]}}
{"xml_path": "/Users/leo/Desktop/520 Project 2/ctg-public-xml/NCT0000xxxx/NCT00000105.xml", "nct_id": "NCT00000105", "org_study_id": "2002LS032", "brief_title": "Vaccination With Tetanus and KLH to Assess Immune Responses.", "official_title": "Vaccination With Tetanus Toxoid and Keyhole Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune Responses", "overall_status": "Terminated", "why_stopped": "Replaced by another study.", "phase": "", "study_type": "Observational", "lead_sponsor": "Masonic Cancer Center, University of Minnesota", "collaborators": [], "primary_completion_date": "March 2012", "primary_completion_date_type": "Actual", "completion_date": "March 2012", "completion_date_type": "Actual", "start_date": "July 2002", "start_date_type": "", "study_first_posted": "November 4, 1999", "last_update_posted": "November 29, 2017", "enrollment": "112", "enrollment_type": "Actual", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "Accepts Healthy Volunteers", "conditions": ["Cancer"], "condition_mesh_terms": ["Neoplasms"], "keywords": [], "interventions": [{"type": "Biological", "name": "Intracel KLH Vaccine", "description": "Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml\r\nintramuscularly."}, {"type": "Biological", "name": "Biosyn KLH", "description": "Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml\r\nintramuscularly."}, {"type": "Drug", "name": "Montanide ISA51", "description": "Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL\r\nsterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered\r\ncontents subcutaneously."}, {"type": "Biological", "name": "Tetanus toxoid", "description": "Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATEDÂ® (TT), is a sterile\r\npreparation of refined tetanus toxoid for intramuscular use only."}], "intervention_mesh_terms": ["keyhole-limpet hemocyanin", "montanide ISA 51", "Tetanus Toxoid"], "primary_outcomes": ["To assess whether patients can mediate an appropriate immune response KLH"], "secondary_outcomes": ["Tetanus Response"], "number_of_arms": "", "number_of_groups": "3", "locations": {"facility_count": 1, "countries": ["United States"]}}
{"xml_path": "/Users/leo/Desktop/520 Project 2/ctg-public-xml/NCT0000xxxx/NCT00000106.xml", "nct_id": "NCT00000106", "org_study_id": "NCRR-M01RR03186-9943", "brief_title": "41.8 Degree Centigrade Whole Body Hyperthermia for the Treatment of Rheumatoid Diseases", "official_title": "", "overall_status": "Unknown status", "why_stopped": "", "phase": "N/A", "study_type": "Interventional", "lead_sponsor": "National Center for Research Resources (NCRR)", "collaborators": [], "primary_completion_date": "", "primary_completion_date_type": "", "completion_date": "", "completion_date_type": "", "start_date": "", "start_date_type": "", "study_first_posted": "January 19, 2000", "last_update_posted": "June 24, 2005", "enrollment": "", "enrollment_type": "", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "conditions": ["Rheumatic Diseases"], "condition_mesh_terms": ["Rheumatic Diseases"], "keywords": ["Rheumatoid Diseases"], "interventions": [{"type": "Device", "name": "Whole body hyperthermia unit", "description": ""}], "intervention_mesh_terms": [], "primary_outcomes": [], "secondary_outcomes": [], "number_of_arms": "", "number_of_groups": "", "locations": {"facility_count": 1, "countries": ["United States"]}}
{"xml_path": "/Users/leo/Desktop/520 Project 2/ctg-public-xml/NCT0000xxxx/NCT00000107.xml", "nct_id": "NCT00000107", "org_study_id": "NCRR-M01RR00109-0737", "brief_title": "Body Water Content in Cyanotic Congenital Heart Disease", "official_title": "", "overall_status": "Completed", "why_stopped": "", "phase": "", "study_type": "Observational", "lead_sponsor": "National Center for Research Resources (NCRR)", "collaborators": [], "primary_completion_date": "", "primary_completion_date_type": "", "completion_date": "", "completion_date_type": "", "start_date": "", "start_date_type": "", "study_first_posted": "January 19, 2000", "last_update_posted": "June 24, 2005", "enrollment": "", "enrollment_type": "", "gender": "All", "minimum_age": "17 Years", "maximum_age": "60 Years", "healthy_volunteers": "Accepts Healthy Volunteers", "conditions": ["Heart Defects, Congenital"], "condition_mesh_terms": ["Heart Defects, Congenital"], "keywords": ["Cyanotic Congenital Heart Disease"], "interventions": [], "intervention_mesh_terms": [], "primary_outcomes": [], "secondary_outcomes": [], "number_of_arms": "", "number_of_groups": "", "locations": {"facility_count": 1, "countries": ["United States"]}}
